Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. on July 13, 2020. The report addresses Item 8.01 (Other Events) concerning the ongoing PRISM Phase 2b/3 clinical trial for Haduvio (nalbuphine ER), an investigational drug for severe pruritus in patients with prurigo nodularis.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial operational updates.
Material Changes and Clinical Trial Updates
- Sample Size Re-estimation: The independent Data Monitoring Committee (DMC) recommended increasing the PRISM trial enrollment target from 240 to 360 subjects following a pre-specified interim conditional power assessment.
- Current Status: Approximately 140 subjects have enrolled, and the number of active sites has increased to more than 60 globally.
- Statistical Power: The increased sample size is intended to maintain statistical power for the trial's primary endpoint.
Guidance, Outlook, and Risks
Timeline Outlook: Due to the increased trial size and COVID-19 related restrictions, the Company expects to complete enrollment in the third quarter of 2021 and report top-line data in the fourth quarter of 2021.
Branding: The Company intends to use "Haduvio" as the trade name for the nalbuphine ER investigational product in future materials.
Risks and Contingencies:
- Uncertainties regarding the success, cost, and timing of clinical trials.
- Impact of the COVID-19 pandemic on clinical operations and enrollment.
- Regulatory developments and the risk that positive interim results may not predict future trial outcomes.
- Haduvio remains an investigational product; safety and efficacy have not been fully evaluated by regulatory authorities.
Key Facts for Investor Verification
- Verify the updated enrollment timeline (Q3 2021) and data readout date (Q4 2021) against subsequent company announcements.
- Monitor the impact of the increased trial size (360 subjects) on the Company's cash burn rate and capital requirements.
- Confirm the status of the 60+ active clinical sites and enrollment progress in future filings.
- Review the Company's most recent Form 10-Q for detailed financial position and liquidity status, as this 8-K does not contain financial statements.